Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV3 | Q8NET8 | 8/20 | 0.34 |
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MITF | O75030 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19098399 | 0.84 | TRPV3 (0.33) | TRPV3 | |
| SCHEMBL19083166 | 0.84 | TRPV3 (0.33) | TRPV3 | |
| SCHEMBL19098405 | 0.83 | NCF1 (0.35) | NCF1NAMPTKMT2ACHRM3DRD2 | |
| SCHEMBL19122465 | 0.83 | CHRM3 (0.34) | TRPV3MEN1KMT2ACHRM3DRD2 | |
| SCHEMBL23841785 | 0.78 | NCF1 (0.40) | NCF1NAMPTMEN1MITFKMT2A | |
| SCHEMBL25658564 | 0.78 | NCF1 (0.40) | NCF1NAMPTMEN1MITFKMT2A | |
| SCHEMBL13713090 | 0.78 | NCF1 (0.40) | NCF1NAMPTMEN1MITFKMT2A | |
| SCHEMBL23025166 | 0.77 | TRPV3 (0.38) | TRPV3 | |
| SCHEMBL23275869 | 0.77 | TRPV3 (0.38) | TRPV3 | |
| SCHEMBL23847788 | 0.73 | NCF1 (0.33) | NCF1NAMPTDRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017120164-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | Tabomedex Biosciences, LLC (US) | 2017-07-13 | — | — | WO | disclosed |
| US-20170190713-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | WUXI APPTEC (HONG KONG) CO., LIMITED (HK) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190713-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | MKNK2, CYP2J2, PTGS2 | TRPV3 2843/4885NCF1 3397/4885NAMPT 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.